ATE316572T1 - Attenuierte rekombinante stabile tollwutvirusmutanten und lebendimpfstoffe - Google Patents

Attenuierte rekombinante stabile tollwutvirusmutanten und lebendimpfstoffe

Info

Publication number
ATE316572T1
ATE316572T1 AT02076485T AT02076485T ATE316572T1 AT E316572 T1 ATE316572 T1 AT E316572T1 AT 02076485 T AT02076485 T AT 02076485T AT 02076485 T AT02076485 T AT 02076485T AT E316572 T1 ATE316572 T1 AT E316572T1
Authority
AT
Austria
Prior art keywords
rabies virus
live vaccines
attenuated recombinant
virus mutants
recombinant stable
Prior art date
Application number
AT02076485T
Other languages
English (en)
Inventor
T Mebatsion
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of ATE316572T1 publication Critical patent/ATE316572T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02076485T 2001-04-23 2002-04-17 Attenuierte rekombinante stabile tollwutvirusmutanten und lebendimpfstoffe ATE316572T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01201464 2001-04-23
EP01203773 2001-10-05

Publications (1)

Publication Number Publication Date
ATE316572T1 true ATE316572T1 (de) 2006-02-15

Family

ID=26076884

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02076485T ATE316572T1 (de) 2001-04-23 2002-04-17 Attenuierte rekombinante stabile tollwutvirusmutanten und lebendimpfstoffe

Country Status (10)

Country Link
US (1) US6887479B2 (de)
EP (1) EP1253197B1 (de)
AR (1) AR033873A1 (de)
AT (1) ATE316572T1 (de)
BR (1) BR0201366A (de)
CA (1) CA2382993A1 (de)
DE (1) DE60208854T2 (de)
ES (1) ES2257505T3 (de)
PT (1) PT1253197E (de)
TR (1) TR200201081A3 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1768697B1 (de) * 2004-07-12 2010-06-02 Thomas Jefferson University Zusammensetzungen mit rekombinantem tollwutvirus
BRPI0617373B1 (pt) 2005-10-14 2022-04-05 The Goverment of The United States of America, Representado por, The Secretary of The Department of Health and Human Services, Centers for Disease Control and Prevention Composições e métodos do vírus da raiva
US20100278864A1 (en) * 2005-12-14 2010-11-04 University Of Georgia Research Foundation, Inc. Rabies Vaccine
FR2944292B1 (fr) 2009-04-08 2013-08-23 Sanofi Pasteur Procede de purification du virus rabique
RU2013102929A (ru) 2010-06-24 2014-07-27 Зе Гавермент Оф Зе Юнайтед Стейтс Оф Америка Эз Репрезентед Бай Зе Секретари Оф Зе Департмент Оф Хэлс Энд Хьюман Сервисез, Сентерз Фо Дизиз Контрол Энд Привеншн Пан-лиссавирусные вакцины против бешенства
WO2012106490A1 (en) 2011-02-03 2012-08-09 The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Multivalent vaccines for rabies virus and filoviruses
US11041170B2 (en) 2016-04-04 2021-06-22 Thomas Jefferson University Multivalent vaccines for rabies virus and coronaviruses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143149A0 (en) * 1998-11-27 2002-04-21 Akzo Nobel Nv Stable, attenuated rabies virus mutants and live vaccines thereof

Also Published As

Publication number Publication date
CA2382993A1 (en) 2002-10-23
EP1253197A1 (de) 2002-10-30
PT1253197E (pt) 2006-06-30
EP1253197B1 (de) 2006-01-25
AR033873A1 (es) 2004-01-07
ES2257505T3 (es) 2006-08-01
DE60208854T2 (de) 2006-08-17
DE60208854D1 (de) 2006-04-13
TR200201081A2 (tr) 2002-11-21
US6887479B2 (en) 2005-05-03
TR200201081A3 (tr) 2002-11-21
BR0201366A (pt) 2003-06-10
US20020164356A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
CY2016018I2 (el) Εμβολιο κατα του ιου του δυτικου νειλου
DE69923434D1 (de) Adjuvierte rekombinante Lebendimpfstoffe gegen Influenza- oder Herpesviren
DK1390066T3 (da) Vaccinesammensætning
FR14C0016I2 (fr) Vacccin west nile
DE60124863D1 (de) Gegen menschliche interleukin-1-beta gerichtete rekombinante antikörper
AU4932601A (en) Recombinant parainfluenza virus expression systems and vaccines
EP1372711A4 (de) Zusammensetzungen und verfahren mit west-nil-virus-polypeptiden
IL158428A0 (en) Vaccine composition comprising at least one hiv virus antigen
EP1575601A4 (de) Rekombinanteimpfstoffviren, die il-15 exprimieren, sowie verfahren zu ihrer verwendung
IL200747A0 (en) Subunits of the enteritis hemorrhagic virus fiber protein and uses thereof as vaccines
EP1497654A4 (de) Immunoglobulin-e-vakzine und verwendungsverfahren dafür
NO20030239L (no) Modifisert virus
DK1749885T3 (da) Infektiøs og svækket kvægdiarévirus
IL162236A0 (en) Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
PL373675A1 (en) Hepatitis b virus treatment
DK2116257T3 (da) Parenterale vaccineformuleringer og anvendelser deraf
ATE316572T1 (de) Attenuierte rekombinante stabile tollwutvirusmutanten und lebendimpfstoffe
IS5777A (is) Bóluefnisvakið lifrarbólgu B veiruafbrigði og notkun þess
EP1651258A4 (de) Hepatitis virus kern-proteine als vakzine-plattformen und anwendungsverfahren dafür
ATE356202T1 (de) Attenuierte stabile tollwutvirusmutante und lebende impfstoffe
DK1248650T3 (da) Forbedrede DNA-vacciner til bovint herpesvirus 1
DE60226057D1 (de) Geflügelkrankheit verursachendes bakterium und daraus stammender impfstoff
IL149173A0 (en) Attenuated recombinant rabies virus mutants and live vaccines thereof
DK1180041T3 (da) Vaccine med ISA-virus
DK2258850T3 (da) Rekombinante virusbaserede malariavacciner

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1253197

Country of ref document: EP

REN Ceased due to non-payment of the annual fee